Coral Laboratories Limited share price
BSE: CORALAB
Key numbers
- Market cap
- ₹ 201 Cr
- Current price
- ₹ 562.75
- 52-week high / low
- ₹ 679 / 360
- Stock P/E
- 10.5
- Book value
- ₹ 585.2
- Dividend yield
- 0.36%
- ROCE
- 11.1%
- ROE
- 8.0%
- Debt to equity
- 0.02
- Sales growth (3 yrs)
- 2.7%
- Profit growth (3 yrs)
- 36.4%
- 1-year return
- 7.7%
About Coral Laboratories Limited
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethiopia, and internationally. The company offers non-sterile products, including antibiotics/antibacterial, antifungal, gastro-intestinal drugs, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, muscle relaxants, cough suppressant/expectorant, anticold, antiallergic, anti-asthmatic, cardiovascular medicines, anti-diabetic, anthelmentic, anti-protozoal/anti-amebic, antimalarial drugs, antipsychotic drugs, and thyroid products; topical, oral antiseptic, and calcium preparations; mouthwashes; nutritional, protein, and iron supplements; kits; appetizers; and other products. It also provides sterile products, such as small volume liquid, cephalosporin, betalactam, and lyophilized injectables; eye, ear, and nose drops; nasal sprays and metered dose inhalers; and large volume parenteral. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/phytochemicals, multivitamins, and nutrients, as well as OTC products. Coral Laboratories Limited was incorporated in 1994 and is headquartered in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 19 | 19 | 22 | 26 | 30 |
| Operating profit | 2 | 5 | 2 | 6 | 5 |
| Net profit | 3 | 6 | 3 | 5 | 5 |
| EPS (₹) | 7.18 | 16.29 | 7.77 | 14.62 | 15.08 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.